Akcea Therapeutics and Ambry Genetics are partnering to offer no-cost, confidential genetic testing and confidential genetic counseling to patients suspected of having or clinically diagnosed with hATTR amyloidosis through the hATTR Compass program.
hATTR Compass is designed to:
- Help accelerate or confirm the diagnosis of hATTR amyloidosis
- Provide support and resources to patients, caregivers and healthcare professionals throughout the genetic testing process
- Empower patients and their healthcare professionals to make the most informed decisions about their health care